DaVita Q2 2022 EPS $2.30, revenue $2.93B; six-month net income down 27% YoY

DAVITA INC.

2022-Q2 EPS reported $3.90 revenue$5,744,312,000

Q2 2022 revenue $2.927B, operating income $433M, diluted EPS $2.30 (vs Q1 2022 EPS $1.61).
Six-month net income $387M ($3.90/sh) vs $531M ($4.72/sh) in prior year, down 27%.
U.S. normalized non-acquired treatment growth was -1.9% YoY; per-day treatments up 0.9% QoQ.
Patient care costs per treatment improved to $247.14 (Q2) from $252.61 (Q1); G&A rose to $241M.
Repurchased 3.9M shares at $95.56 in Q2; additional 0.9M at $82.94 in July.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.